Use of PARP-1 inhibitors in breast cancer 1 (BRCA1) or breast cancer 2 (BRCA2) mutated tumors leads to synthetic lethality by making them highly sensitive to CDDP and other DNA damaging agents [16, 17]. This evidence concerns the gene BRCA1 and cancer.